Welcome to our dedicated page for Annexon news (Ticker: ANNX), a resource for investors and traders seeking the latest updates and insights on Annexon stock.
Annexon, Inc. (Nasdaq: ANNX) is a biopharmaceutical company developing complement inhibitors and targeted immunotherapies for serious neuroinflammatory and classical complement-mediated diseases. The Annexon news feed on Stock Titan aggregates company announcements, clinical updates, regulatory milestones and capital markets activity related to its C1q-focused platform.
Recent news highlights Annexon’s late-stage programs, including tanruprubart for Guillain-Barré syndrome (GBS), vonaprument for dry age-related macular degeneration with geographic atrophy (GA), and ANX1502, an oral C1s inhibitor for autoimmune conditions such as cold agglutinin disease. Investors can follow updates on the European Marketing Authorization Application for tanruprubart in GBS, plans for a Biologics License Application in the U.S., and progress of the global Phase 3 ARCHER II trial of vonaprument in GA.
News items also cover proof-of-concept work for ANX1502, financial results, public offerings of common stock and pre-funded warrants, and participation in major healthcare and investor conferences. Annexon regularly reports on its cash runway, research and development spending, and key anticipated milestones across its portfolio.
This page provides a centralized view of Annexon’s press releases and related coverage, allowing readers to track clinical data readouts, regulatory submissions, financing transactions and corporate presentations as the company advances its complement-based neuroinflammation platform.
Annexon reported third quarter 2020 results on November 16, showcasing a cash balance of $370.7 million as of September 30, 2020, bolstered by a successful IPO. The company has initiated a Phase 2 trial for ANX005 in Huntington’s Disease and completed enrollment in a Phase 1b trial for Guillain-Barré Syndrome (GBS). R&D expenses increased to $11.8 million and net loss widened to $15.6 million. The company is well-capitalized to advance several crucial clinical trials targeting complement-mediated diseases.
Annexon has initiated a Phase 2 study for its monoclonal antibody ANX005, targeting Huntington's Disease (HD). The trial aims to dose 24 patients and assess safety, tolerability, and biomarkers related to neurodegeneration. ANX005 works by inhibiting C1q, a protein implicated in synapse loss and neuroinflammation. The company, focused on complement-mediated disorders, anticipates initial trial results in H2 2021. It has previously received fast track and orphan drug designations for ANX005 in Guillain-Barré Syndrome.
Annexon has reported its second quarter 2020 financial results, highlighting a completed $263 million IPO in July and a private financing round in June that raised $96.8 million. The company is set to initiate four new clinical trials by year-end, including trials for ANX005 in expanded indications. As of June 30, 2020, cash and cash equivalents reached $124.8 million, a significant increase from $43.9 million at the end of 2019. However, net loss for the quarter amounted to $12.5 million, higher than the previous year's loss of $9.7 million.
Annexon, Inc. (Nasdaq: ANNX) has appointed Michael Overdorf as Chief Business Officer, effective July 30, 2020. Overdorf brings nearly 20 years of pharmaceutical experience, having spent 19 years at Eli Lilly in various leadership positions, including Corporate Business Development. His expertise will support Annexon's strategic commercial and business development efforts, especially concerning its promising pipeline of therapies targeting classical complement-mediated disorders. CEO Douglas Love expressed confidence in Overdorf's role to enhance corporate growth and patient access to therapeutic alternatives.
Annexon, Inc. (Nasdaq: ANNX) announced the closing of its initial public offering of 14,750,000 shares of common stock at $17.00 per share, generating approximately $250.8 million in gross proceeds. The stock began trading on July 24, 2020, with a 30-day option for underwriters to purchase an additional 2,212,500 shares. J.P. Morgan, BofA Securities, and Cowen are the joint book-running managers. This follows the effective registration of the offering on July 23, 2020. Annexon focuses on therapies for classical complement-mediated disorders, with an emphasis on autoimmune and neurodegenerative diseases.